Evaluating [68Ga]-Ga PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. PET/CT Images Acquisition
2.2. Image Analysis
2.3. Data Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hopstaken, J.S.; Bomers, J.G.R.; Sedelaar, M.J.P.; Valerio, M.; Fütterer, J.J.; Rovers, M.M. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur. Urol. 2022, 81, 5–33. [Google Scholar] [CrossRef] [PubMed]
- Sanda, M.G.; Cadeddu, J.A.; Kirkby, E.; Chen, R.C.; Crispino, T.; Fontanarosa, J.; Freedland, S.J.; Greene, K.; Klotz, L.H.; Makarov, D.V.; et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J. Urol. 2018, 199, 683–690. [Google Scholar] [CrossRef] [PubMed]
- Reddy, D.; Peters, M.; Shah, T.T.; van Son, M.; Tanaka, M.B.; Huber, P.M.; Lomas, D.; Rakauskas, A.; Miah, S.; Eldred-Evans, D.; et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur. Urol. 2022, 81, 407–413. [Google Scholar] [CrossRef] [PubMed]
- Roach, M.; Hanks, G.; Thames, H.; Schellhammer, P.; Shipley, W.U.; Sokol, G.H.; Sandler, H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 2006, 65, 965–974. [Google Scholar] [CrossRef] [PubMed]
- Kongnyuy, M.; Lipsky, M.J.; Islam, S.; Robins, D.J.; Hager, S.; Halpern, D.M.; Kosinski, K.E.; Schiff, J.T.; Corcoran, A.T.; Wenske, S.; et al. Predictors of biochemical recurrence after primary focal cryosurgery (hemiablation) for localized prostate cancer: A multi-institutional analytic comparison of Phoenix and Stuttgart criteria. Urol. Oncol. Semin. Orig. Investig. 2017, 35, 530.e15–530.e19. [Google Scholar] [CrossRef] [PubMed]
- Cornford, P.; Van Den Bergh, R.C.N.; Briers, E.; Van Den Broeck, T.; Brunckhorst, O.; Darraugh, J.; Eberli, D.; De Meerleer, G.; De Santis, M.; Farolfi, A.; et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2024, 86, 148–163. [Google Scholar] [CrossRef] [PubMed]
- Windisch, O.; Valerio, M.; Yee, C.-H.; Gontero, P.; Bakir, B.; Kastner, C.; Ahmed, H.U.; De Nunzio, C.; De La Rosette, J. Biopsy strategies in the era of mpMRI: A comprehensive review. Prostate Cancer Prostatic Dis. 2024. [Google Scholar] [CrossRef] [PubMed]
- Afshar-Oromieh, A.; Avtzi, E.; Giesel, F.L.; Holland-Letz, T.; Linhart, H.G.; Eder, M.; Eisenhut, M.; Boxler, S.; Hadaschik, B.A.; Kratochwil, C.; et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 197–209. [Google Scholar] [CrossRef] [PubMed]
- Burger, I.A.; Gafita, A.; Müller, J.; Kranzbühler, B.; Donati, O.F.; Eberli, D. 18F-Choline PET/MR Can Detect and Delineate Local Recurrence After High-Intensity Focused Ultrasound Therapy of Prostate Cancer. Clin. Nucl. Med. 2018, 43, e111–e112. [Google Scholar] [CrossRef] [PubMed]
- Burger, I.A.; Müller, J.; Donati, O.F.; Ferraro, D.A.; Messerli, M.; Kranzbühler, B.; Ter Voert, E.E.G.W.; Muehlematter, U.J.; Rupp, N.J.; Mortezavi, A.; et al. 68Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. J. Nucl. Med. 2019, 60, 1118–1123. [Google Scholar] [CrossRef] [PubMed]
- Seifert, R.; Emmett, L.; Rowe, S.P.; Herrmann, K.; Hadaschik, B.; Calais, J.; Giesel, F.L.; Reiter, R.; Maurer, T.; Heck, M.; et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur. Urol. 2023, 83, 405–412. [Google Scholar] [CrossRef] [PubMed]
- Baco, E.; Gelet, A.; Crouzet, S.; Rud, E.; Rouvière, O.; Tonoli-Catez, H.; Berge, V.; Chapelon, J.-Y.; Eggesbø, H.B. Hemi salvage high-intensity focused ultrasound (HIFU) in unilateral radiorecurrent prostate cancer: A prospective two-centre study. BJU Int. 2014, 114, 532–540. [Google Scholar] [CrossRef] [PubMed]
- Hsu, I.-C.J.; Yamada, Y.; Assimos, D.G.; D’Amico, A.V.; Davis, B.J.; Frank, S.J.; Gottschalk, A.R.; Gustafson, G.S.; McLaughlin, P.W.; Nguyen, P.L.; et al. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy 2014, 13, 27–31. [Google Scholar] [CrossRef] [PubMed]
- Rovera, G.; Grimaldi, S.; Oderda, M.; Marra, G.; Calleris, G.; Iorio, G.C.; Falco, M.; Grossi, C.; Passera, R.; Campidonico, G.; et al. Comparative Performance of 68Ga-PSMA-11 PET/CT and Conventional Imaging in the Primary Staging of High-Risk Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy. Diagnostics 2024, 14, 1964. [Google Scholar] [CrossRef] [PubMed]
- Zhou, J.; Wu, R.; Wang, W.; Zhao, Y.; Liu, X. 68Ga-PSMA PET/CT for the evaluation of metastasis in patients with prostate cancer: A systematic review and meta-analysis. Hell. J. Nucl. Med. 2022, 25, 297–311. [Google Scholar] [CrossRef] [PubMed]
- Duan, H.; Ghanouni, P.; Daniel, B.; Rosenberg, J.; Davidzon, G.A.; Aparici, C.M.; Kunder, C.; Sonn, G.A.; Iagaru, A. A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy. J. Nucl. Med. 2023, 64, 592–597. [Google Scholar] [CrossRef]
- Mena, E.; Lindenberg, M.L.; Turkbey, I.B.; Shih, J.H.; Harmon, S.A.; Lim, I.; Lin, F.; Adler, S.; Eclarinal, P.; McKinney, Y.L.; et al. 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy. J. Nucl. Med. 2020, 61, 881–889. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Data | |
---|---|---|
n | 22 | |
Age (y) | 67 (63–71) | |
PSA at PET/CT (ng/mL) | 2.8 (1.5–3.7) | |
Biopsy, ISUP grade group | ||
1 | 7 | (32%) |
2 | 2 | (9%) |
3 | 6 | (27%) |
4 | 2 | (9%) |
5 | 1 | (5%) |
Unknown | 4 | (18%) |
Type of treatment | ||
HIFU | 7 | (32%) |
Brachytherapy | 15 | (68%) |
Continuous data are median and range |
Characteristic | Data | |
---|---|---|
n | 22 | |
Time from treatment to PET/CT scan (mo) | 72 (17–90) | |
PSA at PET/CT scan (ng/mL) | 2.8 (1.5–3.7) | |
PET/CT findings | ||
Positive | 14 | (64%) |
Negative | 8 | (36%) |
Positive scans after HIFU | 6 | (86%) |
Positive scans after brachytherapy | 8 | (53%) |
TNM (n = 14) | ||
T | ||
miT2 | 3 | (21%) |
miT3 | 5 | (36%) |
N | ||
miN1 | 3 | (21%) |
miN2 | 1 | (7%) |
M | ||
miM1a | 4 | (29%) |
miM1b | 1 | (7%) |
TNM classification based on PROMISE criteria [11] | ||
Continuous data are median and range |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Di Giorgio, A.; Rapa, M.; Civollani, S.; Farolfi, A.; Fanti, S. Evaluating [68Ga]-Ga PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective Study. Curr. Oncol. 2025, 32, 9. https://doi.org/10.3390/curroncol32010009
Di Giorgio A, Rapa M, Civollani S, Farolfi A, Fanti S. Evaluating [68Ga]-Ga PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective Study. Current Oncology. 2025; 32(1):9. https://doi.org/10.3390/curroncol32010009
Chicago/Turabian StyleDi Giorgio, Andrea, Marco Rapa, Simona Civollani, Andrea Farolfi, and Stefano Fanti. 2025. "Evaluating [68Ga]-Ga PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective Study" Current Oncology 32, no. 1: 9. https://doi.org/10.3390/curroncol32010009
APA StyleDi Giorgio, A., Rapa, M., Civollani, S., Farolfi, A., & Fanti, S. (2025). Evaluating [68Ga]-Ga PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective Study. Current Oncology, 32(1), 9. https://doi.org/10.3390/curroncol32010009